EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance

Changwen Xue, Chao Wu, Yingjin Zhang, Wenyu Yang, Yao Zou, Ye Guo, Yueshen Ma, Yumei Chen, Xiaojuan Chen, Xiaofan Zhu, Li Zhang

Annals of Hematology · 06.05.2026 · 105 (7)

DOI: 10.1007/s00277-026-07028-7 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Annals of Hematology, online erschienen am 06.05.2026. Verfasst von Changwen Xue und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clin…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, CAMS Innovation Fund for Medical Sciences, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificPrecursor B-Cell Lymphoblastic Leukemia-LymphomaHumansNeoplasm, ResidualFemaleMaleChildChild, PreschoolAdolescentRemission InductionTreatment OutcomeInfant

Stichwörter der Autor:innen

B-cell acute lymphoblastic leukemiaBlinatumomabImmunotherapyMinimal residual diseasePediatric

Substanzen

blinatumomabAntibodies, Bispecific

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sc…
  • Tianjin Institutes of Health Science, Tianjin, 301600, China.
  • Tianjin Institutes of Health Science, Tianjin, 301600, China. zhangli1@ihcams.ac.cn.

Förderung

  • National Key Research and Development Program of China
  • CAMS Innovation Fund for Medical Sciences
  • National Natural Science Foundation of China
  • Haihe Laboratory of Cell Ecosystem Innovation Fund

Zitieren

APA

Xue, C., Wu, C., Zhang, Y., Yang, W., Zou, Y., Guo, Y., Ma, Y., Chen, Y., Chen, X., Zhu, X., & Zhang, L. (2026). Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance. Annals of Hematology, 105(7). https://doi.org/10.1007/s00277-026-07028-7

Vancouver

Xue C, Wu C, Zhang Y, Yang W, Zou Y, Guo Y, et al. Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance. Annals of Hematology. 2026;105(7). doi:10.1007/s00277-026-07028-7

BibTeX
@article{Xue2026,
  author = {Xue, Changwen and Wu, Chao and Zhang, Yingjin and Yang, Wenyu and Zou, Yao and Guo, Ye and Ma, Yueshen and Chen, Yumei and Chen, Xiaojuan and Zhu, Xiaofan and Zhang, Li},
  title = {Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {7},
  doi = {10.1007/s00277-026-07028-7}
}
Kostenlos starten →